Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy-to-use oral rinsing […]
Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced the publication of the study titled “Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization” […]
Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, announced that they are making great progress enrolling patients in their clinical trial. “We are primarily enrolling patients in our oral mucositis program AG013 and […]
Oragenics Presents Interim Data on the AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
UF startup Oragenics, Inc., a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, announced initial data from its ongoing Phase 2, placebo-controlled, clinical trial of AG013 in oral mucositis presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain. […]
Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium
UF startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced it will be presenting a talk titled “Lantibiotics, a Novel Class of Antibiotics in the Pharmacopeia,” which will be part of a session dedicated to novel antimicrobial developments to counter multidrug-resistant bacterial infections […]
Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action
UF Innovate | Sid Martin Biotech client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), announces the publication of a collaborative study investigating an additional mechanism of action of the company’s lantibiotic compounds, which shows the formation of water permeating pores across bacterial […]
BSI Team Joins Forces With Oragenics in Search for New Antibiotics
A biophysics team led by Florida International University researchers Prem Chapagain and Bernard Gerstman has joined forces with UF Innovate | Sid Martin Biotech resident client Oragenics Inc. in an effort that could lead to the development of new compounds to treat life-threatening infections. Oragenics develops antibiotics that can be used against infectious diseases and […]
Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
UF Innovate | Sid Martin Biotech resident client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced the enrollment of the 60th patient in its Phase 2 double-blind, placebo-controlled clinical trial of AG013. AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactisbacteria […]
Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716
UF startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), announced the publication of a preclinical study using the lead compound from its lantibiotics program, OG716, in the peer-reviewed journal, Antimicrobial Agents and Chemotherapy. Oragenics is an alumnus of UF Innovate | Sid […]
Oragenics Receives Approval for Phase 2 Study (Pharmacy Choice)
UF Innovate | Sid Martin Biotech alumni startup Oragenics announced that it has been approved in Belgium to enroll patients in its Phase 2 trial for its drug AG013 for a mouth disorder, Oral Mucositis (OM). Receiving this clearance and allowing the company to expand its trial globally gives it an advantage to finish the […]